Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.02−0.08 (-1.13%)
Close on Nov 17, 2026Market cap $254.77MP/E –Yield –
Evommune operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Evommune's operating cash flow for the twelve months ending Sep 30, 2026 was -$90.40M. For fiscal 2025 it was -$76.44M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.44M | – |
| FY2024 | Dec 31, 2024 | -$58.20M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$20.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.64M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.51M | – |
See a number that looks wrong?